Immunocore, Ltd. (Immunocore)

Oncology Corporate Profile

Company Description

Immunocore, headquartered in Abingdon, Oxfordshire, United Kingdom, is a privately owned, clinical-stage, biotechnology company discovering and developing highly innovative biotherapeutics known as ImmTACs for the treatment of cancer and a range of other serious diseases. Its world-leading proprietary T Cell Receptor (TCR) technology exploits the power of the body's own immune system to find and kill diseased cells. Immunocore has established a robust technology platform which has yielded an ImmTAC clinical candidate, IMCgp100, currently in Phase I/II clinical trials in melanoma patients in both the US and UK.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
IMCgp100 (+ merestinib)immunotherapyMelanomaIEli Lilly
IMCgp100 (+ durvalumab and tremelimumab )immunotherapyMelanomaIEli Lilly
IMCgp100 (+ galunisertib)immunotherapyMelanomaIEli Lilly

View additional information on product candidates here »


Recent News Headlines

There are no news items to display